ClinicalTrials.gg
Enrolling by invitationNCT07393373Updated Aug 26, 2026

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

A Phase 2 interventional study of Infigratinib in Hypochondroplasia, sponsored by QED Therapeutics, a BridgeBio company. Enrolling by invitation at 24 sites in 10 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by QED Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Mucopolysaccharidosis IV with a site in United States — 16 open to participants now, 18 under way, 1 of them phase 3. Mucopolysaccharidosis IV · United States.

Planned enrollment
8th of 30
135 · median 88
Started
2026
with 3 others
Phase 2
10 of 56
3 open now
Primary completion
2036-05
later than 16 of 17 live
Registered
51st of 56
by date
Lead sponsor
8 of 56
QED Therapeutics, a BridgeBio company

Among the 56 studies in Mucopolysaccharidosis IV with a site in United States, this one is the 8th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 16 of the 17 other live ones, and was the 51st registered.

Mucopolysaccharidosis IV

101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.

Browse Mucopolysaccharidosis IV studies →

Open to participants now

16 of the 56 studies in Mucopolysaccharidosis IV with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Mucopolysaccharidosis IV with a site in United States, or all of them as a file.
02

Study summary

Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.

03

Conditions studied

  • Hypochondroplasia

Keywords

  • skeletal dysplasia
  • endochondral ossification
  • hypochondroplasia
  • HCH
  • shortened proximal limbs
  • fibroblast growth factor receptor 3
  • FGFR3
  • endochondral bone formation
  • disproportionate short stature
  • quality of life
  • dwarfism
  • bone diseases
  • musculoskeletal diseases
  • osteochondrodysplasia
  • functional abilities
  • annualized growth velocity
  • annualized height velocity
  • growth
  • genetic diseases
  • congenital
  • AHV
  • AGV
  • Pathogenic variants
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion Criteria for Participants Rolling Over from ACCEL 2/3

    1. Pediatric participants with HCH who have completed ACCEL 2/3
    2. Negative pregnancy test in girls ≥10 years of age or girls of any age who have experienced menarche

Exclusion criteria

Exclusion Criteria:

  • Exclusion Criteria for Participants Rolling Over from ACCEL 2/3

    1. Participant has concurrent medical condition that, in the view of the PI and/or sponsor, would interfere with study participation or safety evaluations
    2. Participants who developed a medical condition that requires the initiation of treatment with a prohibited medication
    3. Participants who prematurely discontinued ACCEL 2/3
    4. Participants who have reached final height or near final height
    5. Current participation in an ongoing clinical study with a sponsor other than QED
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Arm 1: Rollover subjects

    Children who have completed QED-sponsored interventional study with infigratinib

    Drug: Infigratinib

Interventions

  • Infigratinib to be administered by mouth and initiated at the last dose level received in the ACCEL 2/3 study or at the dose selected to be further evaluated after proof-of-concept is established for Phase 2 portion of ACCEL 2/3.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAE) and serious TEAE

    Time frame: 10 years

  2. Changes over time in standing height Z-score in relation to HCH and non-HCH growth charts

    Time frame: 10 years

Secondary outcomes

  1. Changes over time in AHV Z-score

    Time frame: 10 years

  2. Changes over time in body proportions

    Time frame: 10 years

  3. Changes over time in weight Z-score

    Time frame: 10 years

  4. Changes overtime in BMI

    Time frame: 10 years

  5. Age of puberty onset and time to Tanner stage ≥4

    Time frame: 10 years

  6. Changes over time in body composition as assessed by DXA (dual x-ray absorptiometry) scans

    Time frame: 10 years

  7. Changes over time in bone morphology/density by x-ray and DXA

    Time frame: 10 years

  8. Change in psychomotor function assessed by age-appropriate computerized tests (Detection Test)

    Time frame: 10 years

  9. Change in attention assessed by age-appropriate computerized tests (Identification Test)

    Time frame: 10 years

  10. Change in visual learning assessed by age-appropriate computerized tests (One Card Learning Test)

    Time frame: 10 years

  11. Change in working memory assessed by age-appropriate computerized tests (One Back Test)

    Time frame: 10 years

  12. Changes over time in severity of epilepsy measured by frequency and adverse event grading

    Time frame: 10 years

  13. Changes in health-related Quality of life [HRQoL] as assessed by Pediatric Quality of Life Inventory (PedsQL)

    Time frame: 10 years

  14. Changes in health-related Quality of life [HRQoL] as assessed by Quality of Life in Short Stature Youth questionnaire (QoLISSY)

    Time frame: 10 years

  15. Severity of the physical functioning challenges as assessed by Patient/Parent Global Impression of Severity (PGI-S)

    Time frame: 10 years

  16. Severity of the physical functioning challenges as assessed by Patient/Parent Global Impression of Change (PGI-C)

    Time frame: 10 years

  17. Subject and caregiver evaluation of treatment benefit as assessed by a qualitative interview

    Time frame: 10 years

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for May 2036, 121 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Feb 6, 2026
StartActual
Apr 23, 2026
Primary completionEst.
May 31, 2036
CompletionEst.
May 31, 2036
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07393373
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Apr 23, 2026
Primary completion
May 31, 2036 (estimated)
Completion
May 31, 2036 (estimated)
Last update
Aug 26, 2026

Study contacts

QED Therapeutics SVP, Clinical Development
study director · QED Therapeutics, a BridgeBio company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion